GC
ONC

Guggenheim Capital’s BeOne Medicines Ltd ONC Stock Holding History

Guggenheim Capital’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Buy
12,352
+107
+0.9% +$31.5K 0.02% 551
2026
Q1 		$3.64M Buy
12,245
+3,097
+34% +$1M 0.03% 521
2025
Q4 		$2.78M Buy
9,148
+2,118
+30% +$693K 0.02% 580
2025
Q3 		$2.4M Sell
7,030
-1,007
-13% -$306K 0.02% 639
2025
Q2 		$1.95M Sell
8,037
-644
-7% -$158K 0.02% 663
2025
Q1 		$2.36M Buy
8,681
+4,112
+90% +$961K 0.02% 598
2024
Q4 		$844K Buy
+4,569
New +$934K 0.01% 994
2022
Q1 		– Sell
-777
Closed -$211K – 2193
2021
Q4 		$211K Sell
777
-6,499
-89% -$2.19M ﹤0.01% 2019
2021
Q3 		$2.64M Sell
7,276
-1,327
-15% -$434K 0.02% 912
2021
Q2 		$2.95M Buy
8,603
+677
+9% +$224K 0.02% 895
2021
Q1 		$2.76M Sell
7,926
-3,064
-28% -$1.01M 0.02% 867
2020
Q4 		$2.84M Buy
10,990
+4,408
+67% +$1.21M 0.02% 813
2020
Q3 		$1.89M Sell
6,582
-9,862
-60% -$2.32M 0.01% 919
2020
Q2 		$3.1M Buy
16,444
+2,453
+18% +$399K 0.02% 706
2020
Q1 		$1.72M Sell
13,991
-2,935
-17% -$459K 0.02% 851
2019
Q4 		$2.81M Buy
+16,926
New +$2.81M 0.02% 906
2018
Q2 		– Sell
-5,583
Closed -$938K – 2637
2018
Q1 		$938K Buy
5,583
+558
+11% +$75.6K ﹤0.01% 2103
2017
Q4 		$491K Sell
5,025
-13,675
-73% -$1.25M ﹤0.01% 2366
2017
Q3 		$1.94M Sell
18,700
-2,151
-10% -$160K ﹤0.01% 1692
2017
Q2 		$938K Buy
20,851
+801
+4% +$31.6K ﹤0.01% 2113
2017
Q1 		$735K Sell
20,050
-1,999
-9% -$72.8K ﹤0.01% 2257
2016
Q4 		$670K Buy
+22,049
New +$693K ﹤0.01% 2316

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Guggenheim Capital's ONC Position: Q2 2026 in Review

Guggenheim Capital increased its BeOne Medicines Ltd (ONC) stake by 0.87% in Q2 2026, buying an estimated $31.5K and bringing the position to 12,352 shares worth $3.52M. The position accounts for 0.02% of the portfolio, ranked #551.

Guggenheim Capital first reported a position in ONC in Q4 2016 and has held it in 22 quarters since. The position peaked at $3.64M in Q1 2026. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Guggenheim Capital held 12,352 shares of BeOne Medicines Ltd worth $3.52M as of Q2 2026.
  • Guggenheim Capital bought 107 BeOne Medicines Ltd shares in Q2 2026, an estimated $31.5K.
  • BeOne Medicines Ltd made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #551 holding.
  • Guggenheim Capital first reported a position in BeOne Medicines Ltd in Q4 2016 and has held it in 22 quarters since.
  • Guggenheim Capital's BeOne Medicines Ltd position peaked at $3.64M in Q1 2026.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.